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This issue of “Reumatismo” deals with a variety of aspects of chronic wide-
spread pain (CWP) and its rheumatological 
quasi-synonym of fibromyalgia (FM) (1). 
The definitions of CWP and FM both have 
a long history. Chronic musculoskeletal 
pain conditions are universally prevalent 
in both genders and all age groups and, al-
though their pathophysiology varies, they 
are inter-related anatomically and by their 
association with pain and impaired physi-
cal function. However, there is still no con-
sensus as to whether FM should be consid-
ered a discrete entity or just the tip of the 
iceberg of CWP (2). 
Topography can be used if the pain is lo-
calised (e.g. biceps tendinitis) and regional 
syndromes are limited to a body quadrant 
(myofascial pain syndrome) or cavity (vis-
ceral pain referral syndromes), whereas 
CWP is an accepted term if the pain is dif-
fuse and there are few ancillary symptoms, 
and FM should be used if the pain is asso-
ciated with many symptoms or functional 
syndromes. 
The generalised category of CWP implies 
a systemic process that globally affects 
the musculoskeletal system. Furthermore, 
CWP and (particularly) FM are different 
from localised pain conditions not only in 
terms of their bodily distribution, but also 
because of their different impact on peo-
ple’s lives (2, 3) as multiple pain sites are 
associated with more intense and longer-
lasting pain, more severe disability, and a 
higher incidence of anxiety and depression. 
When recording a patient’s clinical history, 
it soon becomes clear that it can take years 
for full-blown chronic pain to develop, and 
that the speed of onset of diffuse pain is 
often related to stressful events or psycho-
affective problems. 
Although they can be considered syn-
onyms, CWP and FM also have different 
epidemiological profiles (2). Wolfe et al. 
[4] observed that the number of patients 
who meet the criteria for FM is about 2% 
of the whole population or two-tenth of 
those with CWP (10% of the population), 
which raises the question of what is the ap-
propriate diagnosis for the remaining 8%. 
FM may be the intersection of a consider-
ably abnormal and reduced pain threshold 
with a series of clinical distress variables 
that include pain, fatigue, sleep distur-
bance, anxiety and depression. Empiri-
cally, central sensitisation can be charac-
terised by using functional brain imaging 
to demonstrate increased pain processing 
or by means of experimental pain and sen-
sory testing. The pain associated with cen-
tral sensitisation has a number of clinical 
characteristics (5). It tends to be multifo-
cal, widely distributed, and associated with 
a long (sometimes life-time) history of 
pain. It is typically familial, more prevalent 
among females, and frequently initiated by 
various “triggers” such as early-life stress-
ful events, physical trauma, catastrophic 
events, infections and peripheral pain syn-
dromes, including inflammatory joint dis-
orders (5, 6). FM can also be suspected in 
the presence of common comorbidities, 
and clinicians should ask about CWP when 
faced by patients with conditions such as 
mood or anxiety disorders that can precede 
the development of FM. Other common 
comorbidities in patients with FM include 
regional pain syndromes that may share 
certain pathophysiological, including irri-
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table bowel syndrome, tension-type head-
ache/migraine, interstitial cystitis or pain-
ful bladder syndrome, chronic prostatitis or 
prostadynia, temporomandibular disorders, 
chronic pelvic pain, and vulvodynia. 
The 1990 American College of Rheumatol-
ogy Research Classification Criteria (1990 
ACR RCC) made FM easier to diagnose 
(7), but various limitations led to them be-
ing replaced by the 2010 criteria (8), which 
replaced the physical examination item of 
tender points by the widespread pain index 
(WPI), a 0-19 count of the number of body 
regions reported to be painful, introduced a 
0-3 severity scale for a series of symptoms 
characteristic of FM (fatigue, unrefreshing 
sleep, cognitive problems, and the extent of 
somatic symptom reporting), which were 
combined to give a 0-12 symptom severity 
(SS) scale. (8). The authors combined the SS 
scale and the WPI to recommend a new case 
definition of fibromyalgia: (WPI > or =7 and 
SS > or =5) or (WPI 3-6 and SS > or =9).
The ability to evaluate and measure FM as 
a condition is likely to provide a number 
of benefits, including the identification of 
treatment responders in clinical trials and 
clinical practice. When evaluating the ef-
fectiveness of FM therapy, it is important 
to be able to assess its impact on all of 
the domains considered important by cli-
nicians and patients, and the OMERACT 
(Outcome Measures in Rheumatology 
Fibromyalgia Syndrome Workshop) has 
recently attempted to include the patient 
perspective in identifying and prioritising 
such domains (9). 
The use of patient-reported outcomes is 
becoming an increasingly accepted method 
of evaluating disease states and manage-
ment strategies in clinical trials, especially 
in the case of chronic pain conditions. In 
agreement with OMERACT, we found that 
three domains (pain, fatigue and sleep) 
could be used to create a self-administered 
Fibromyalgia Activity Score (FAS) for 
evaluating the efficacy of treatment in FM 
patients (10).
Another issue is that all three of the phar-
maceutical agents approved by the Ameri-
can Food and Drug Administration (FDA) 
adequately manage only about 50% of FM 
patients. Effective therapy may ultimately 
depend on the biological identification of 
subgroups of patients who can be expected 
to respond differently to each of a number 
of mechanism-related interventions (11). 
FM treatment requires an individualised 
approach that often involves multimodal, 
multidisciplinary management. A number 
of pharmacotherapies are available that 
are supported by clinical trial data show-
ing their efficacy in treating pain and other 
symptom domains, and these should be 
combined with non-pharmacological mo-
dalities such as cognitive behavioural ther-
apy and exercise (12). 
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